{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:20:06Z","timestamp":1766067606941,"version":"3.37.3"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41375-022-01675-1","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T08:02:58Z","timestamp":1660377778000},"page":"2548-2550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine"],"prefix":"10.1038","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"M.","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Piciocchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3531-4766","authenticated-orcid":false,"given":"M.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Soddu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Martino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Albano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vignetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1809-284X","authenticated-orcid":false,"given":"P.","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"F.","family":"Palandri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"1675_CR1","doi-asserted-by":"publisher","first-page":"4750","DOI":"10.3390\/cancers13194750","volume":"13","author":"F Palandri","year":"2021","unstructured":"Palandri F, Breccia M, De Stefano V, Passamonti F. Philadelphia-negative chronic myeloproliferative neoplasms during the COVID-19 pandemic: challenges and future scenarios. Cancers. 2021;13:4750.","journal-title":"Cancers"},{"key":"1675_CR2","doi-asserted-by":"publisher","first-page":"E200","DOI":"10.1002\/ajh.26159","volume":"96","author":"K Simpson-Poirier","year":"2021","unstructured":"Simpson-Poirier K, Harnois M, Olney HJ, Sirhan S, Gratton MO, Assouline S, et al. Risk of infection in MPN patients in the era of Covid-19: A prospective multicenter study of 257 patients from the CML-MPN Quebec Research Group. Am J Hematol. 2021;96:E200\u2013e203.","journal-title":"Am J Hematol"},{"key":"1675_CR3","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1038\/s41375-020-01032-0","volume":"34","author":"M Breccia","year":"2020","unstructured":"Breccia M, Piciocchi A, De Stefano V, Finazzi G, Iurlo A, Fazi P, et al. COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey. Leukemia. 2020;34:2813\u20134.","journal-title":"Leukemia"},{"key":"1675_CR4","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/S2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737\u2013e745.","journal-title":"Lancet Haematol"},{"key":"1675_CR5","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1038\/s41375-020-0953-3","volume":"34","author":"F Palandri","year":"2020","unstructured":"Palandri F, Piciocchi A, De Stefano V, Breccia M, Finazzi G, Iurlo A, et al. How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey. Leukemia. 2020;34:2805\u20138.","journal-title":"Leukemia"},{"key":"1675_CR6","doi-asserted-by":"crossref","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. REDCap Consortium, The REDCap consortium: Building an international community of software partners. J Biomed Inform. 2019;95:103208.","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"1675_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41375-020-01107-y","volume":"35","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, et al. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021;35:485\u201393.","journal-title":"Leukemia"},{"key":"1675_CR8","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-021-01130-1","volume":"14","author":"F Pimpinelli","year":"2021","unstructured":"Pimpinelli F, Marchesi F, Piaggio G, Giannarelli D, Papa E, Falcucci P, et al. Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia. J Hematol Oncol. 2021;14:119.","journal-title":"J Hematol Oncol"},{"key":"1675_CR9","doi-asserted-by":"publisher","first-page":"106819","DOI":"10.1016\/j.leukres.2022.106819","volume":"116","author":"G Auteri","year":"2022","unstructured":"Auteri G, Bartoletti D, Di Pietro C, Sutto E, Mazzoni C, Romagnoli AD, et al. Longer-term response to SARS-CoV-2 vaccine in MPN patients: role of ruxolitinib and disease severity. Leuk Res. 2022;116:106819.","journal-title":"Leuk Res"},{"key":"1675_CR10","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S2352-3026(21)00169-1","volume":"8","author":"K Maneikis","year":"2021","unstructured":"Maneikis K, Sablauskas K, Ringeleviciut\u00e8 U, Vaitekenaite V, Cekauskiene R, Kryzauskait\u00e9 L, et al. Immunogenicity of the BNT162B2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol. 2021;8:583\u201392.","journal-title":"Lancet Haematol"},{"key":"1675_CR11","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.3390\/biomedicines9101480","volume":"9","author":"F Fiorino","year":"2021","unstructured":"Fiorino F, Sicuranza A, Ciabattini A, Santoni A, Pastore G, Simoncelli M, et al. The slower antibody response in myelofibrosis patients after two doses of mRNA SARS-CoV2 vaccine calls for a third dose. Biomedicines. 2021;9:1480.","journal-title":"Biomedicines"},{"key":"1675_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00579-0","volume":"11","author":"D Cattaneo","year":"2021","unstructured":"Cattaneo D, Bucelli C, Cavallaro F, Consonni D, Iurlo A. Impact of diagnosis and treatment on response to COVID-19 vaccine in patients with BCR-ABL1-negative myeloproliferative neoplasms. A single-center experience. Blood Cancer J. 2021;11:185.","journal-title":"Blood Cancer J"},{"key":"1675_CR13","doi-asserted-by":"publisher","first-page":"E408","DOI":"10.1002\/ajh.26305","volume":"96","author":"P Guglielmelli","year":"2021","unstructured":"Guglielmelli P, Mazzoni A, Maggi L, Kiros ST, Zammarchi L, Pilerci S, et al. Impaired response to first SARS-CoV-2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib. Am J Hematol. 2021;96:E408\u2013E410.","journal-title":"Am J Hematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01675-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01675-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01675-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:11:42Z","timestamp":1664478702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01675-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":13,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1675"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01675-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"type":"print","value":"0887-6924"},{"type":"electronic","value":"1476-5551"}],"subject":[],"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MB received honoraria by Novartis, Pfizer, Incyte, BMS. FP received honoraria by Novartis, Celgene, AOP, Sierra Oncology and CTI. VDS received grants from Amgen, Celgene, Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}